Data / Drug companies / Desvenlafaxine succinate
Desvenlafaxine succinate: 12 companies and 30 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Desvenlafaxine succinate is listed in the FDA National Drug Code Directory by 12 companies, with 30 products in commercial distribution. 27 of the products (90.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, extended release; tablet, film coated, extended release, and the newest product started marketing on December 6, 2023.
The request: Get every company that lists desvenlafaxine succinate in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 12
- Products
- 30
- Generic (ANDA) products
- 27 (90.0%)
- Application numbers
- 4
- Routes
- Oral
- Brand names
- Desvenlafaxine, Pristiq Extended-Release, Desvenlafaxine
- openFDA record search
- api.fda.gov
Companies that list desvenlafaxine succinate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 4 | tablet, film coated, extended release; tablet, extended release | Generic drugs (ANDA) | August 25, 2022 |
| Bryant Ranch Prepack | 4 | tablet, film coated, extended release; tablet, extended release | Generic drugs (ANDA) | August 25, 2022 |
| Alembic Pharmaceuticals Limited | 3 | tablet, extended release | Generic drugs (ANDA) | September 14, 2018 |
| Breckenridge Pharmaceutical, Inc. | 3 | tablet, extended release | Generic drugs (ANDA) | November 28, 2018 |
| Lupin Pharmaceuticals, Inc. | 3 | tablet, film coated, extended release | Generic drugs (ANDA) | August 25, 2022 |
| Preferred Pharmaceuticals Inc. | 3 | tablet, extended release; tablet, film coated, extended release | Generic drugs (ANDA) | December 6, 2023 |
| Wyeth Pharmaceuticals LLC, a Subsidiary of Pfizer Inc. | 3 | tablet, extended release | New drug applications (NDA) | April 1, 2015 |
| Bryant Ranch Prepack | 2 | tablet, extended release | Generic drugs (ANDA) | March 1, 2017 |
| Macleods Pharmaceuticals Limited | 2 | tablet, extended release | Generic drugs (ANDA) | July 30, 2020 |
| Coupler LLC | 1 | tablet, extended release | Generic drugs (ANDA) | March 1, 2017 |
| Direct_Rx | 1 | tablet, extended release | Generic drugs (ANDA) | November 12, 2020 |
| Proficient Rx LP | 1 | tablet, extended release | Generic drugs (ANDA) | March 1, 2017 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, extended release | 21 | 70% |
| Tablet, film coated, extended release | 9 | 30% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 27 | 90% |
| New drug applications (NDA) | 3 | 10% |
Pharmacologic classes
| Class | Products |
|---|---|
| Serotonin and Norepinephrine Reuptake Inhibitor | 30 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.